The ONE is a non-aromatizable, 5 alpha-reduced compound
Thank you thank you, too kind!
No worries.
I have been impressed with the logs and reviews on the one and am planning on using this product very soon for recomp.
MY QUESTION IS: What is the science behind not using a SERM for the product for PCT. This is a WIDELY accepted standard for DS/PH. It is repeatedly encouraged and most believe it is necessary.
6-bromo is a good AI with very low toxicity compared to other AIs. But it just doesnt make sense to me to not use a SERM inversely ramped with a AI.
It seems to be a missing ingredient. And You guys have repeated say a SERM isnt nescessary. This seems counter productive and counter intuitive. Am I missing something? I could be.
Im not being a nay sayer, as I intensely look forward to using The ONE/ Second Gear.
I just want a good scientific reason not to use SERM, other wise I will plan a PCT with SERM.
Please educate me, fill me in.
BTW im listening to the "SUPERHUMAN RADIO review on the ONE". If this answers my question Ill edit my post.
The science behind NOT using a SERM for PCT is because The ONE is a non-aromatizable, 5 alpha-reduced compound.
A brief article below, written specifically for this explanation:
What is the physiological reason that a non-aromatizable 5a-reduced compound cannot give you gyno?
Written by Rosie Chee, BExSpSc
April 2009
What is gyno?
"Gyno" is short for gynecomastia. Gynecomastia is the benign unilateral or bilateral glandular proliferation of the breast tissue in a male[1,2,3].
Pathophysiology of gyno?
Gynecomastia can be caused by a number of factors, including an increase in serum estrogen concentration[1,3], a decrease in serum androgen concentration[1,4], androgen-receptor problem[1,4], genetic variants in aromatase enzymes[5,6], adrenal disorders[3], hypersensitive breast tissue[1], certain drugs, and marijuana use[3]. The most common cause of gynecomastia is the imbalance of hormones, with an increase in estrogenic effects relative to androgenic action at the breast tissue[4,7].
What does 'non-aromatizable' mean?
Non-aromatizable means that the compound has aromatase inhibiting properties; therefore no estrogen transformation can occur from androgens[8].
What is a 5a-reduced compound?
DHT is a potent non-aromatizable androgen receptor agonist[9]. 17a-methyl-etioallocholan-17b-ol-3-hydroxyimine (i.e. The ONE) is a 5a-reduced derivative of DHT. Although a 5a-reduced androgen compound can be metabolized into other androgenic compounds, it cannot aromatize to estrogens[8], because it lacks the capacity to interact with the 5a reductase enzyme, and the 5a-reduction process is an irreversible pathway.
How does a 5a-reduced compound work?
5a-reduced compounds, like most androgens, bind to androgen receptors. 5a-reduced compounds display a stronger binding affinity for intracellular androgen receptors[10,11], and 5a-reduced derivatives of DHT are potent androgens[12].
Why can a non-aromatizable 5a-reduced compound not cause gynecomastia?
The physiological reason that a non-aromatizable 5a-reduced compound cannot give you gynecomastia is because that compound creates the opposite hormonal environment for gynecomastia to form - i.e. no conversion of androgens to estrogen, greater binding affinity to the androgen receptors, greater androgenic potency, etc.; and once a compound has become 5a-reduced this is an irreversible process.
REFERENCE LIST
1 Braunstein, G. D. (1993). Gynecomastia. The New England Journal of Medicine, 328(7). (p. 490-495).
2 Czajka I. & Zgliczyński W. (2005). Gynecomastia: pathogenesis, diagnosis and treatment. Endokrynol Pol, 56(3). (p. 269-277).
3 Marieb, E. (2004). Human anatomy and physiology (6th ed.). San Fransisco, CA, USA: Pearson Benjamin Cummings.
4 Narula, H. S. & Carlson, H. E. (2007). Gynecomastia. Endocrinol Metab Clin North Am, 36(2). (p. 497-519).
5 Hutchison JB. (1993) Aromatase: Neuromodulator in the Control of Behavior. Journal of Steroid Biochemistry and Molecular Biology, 44 (4-6). (p. 509-520).
6 Shinoda K. (1994) Brain Aromatization and its Associated .Structures. Endocrine Journal, 41(2). (p. 115-138).
7 Mathur, R. & Braunstein, G. D. (1997). Gynecomastia: Pathomechanisms and treatment strategies. Horm Res, 48(3). (p. 95-102).
8 Smith, S. S. (2003). Neurosteroid effects in the central nervous system. Brooklyn, New york, USA: CRC Press.
9 Shilling, A. D. & Williams, D. E. (2000). The non-aromatizable androgen, dihydrotestosterone, induces antiestrogenic responses in the rainbow trout. Journal of Steroid Biochemistry and Molecular Biology, 74(4). (p. 187-194).
10 Lemus, A. M., Enríquez, J., García, G. A., Grillasca, I. & Pérez-Palacios, G. (1997). 5α-Reduction of norethisterone enhances its binding affinity for androgen receptors but diminishes its androgenic potency. The Journal of Steroid Biochemistry and Molecular Biology, 60(1-2). (p. 121-129).
11 Tóth, M. & Zakár, T. (1982). Relative binding affinities of testosterone, 19-nortestosterone and their 5 alpha-reduced derivatives to the androgen receptor and to other androgen-binding proteins: a suggested role of 5 alpha-reductive steroid metabolism in the dissociation of "myotropic" and "androgenic" activities of 19-nortestosterone. J Steroid Biochem, 17(6). (p. 653-660).
12 Steimer, T. H. (1993). Steroid hormone metabolism. In A. Campana, J.J. Dreifuss, P. Sizonenko, J.D. Vassalli, J. Villar (Eds.). Reproductive Health. Ares-Serono Symposia Series - Frontiers in Endocrinology, 2. Rome: Ares Serono Symposia Publications.
As a side note:
oxymetholone (anadrol) is the only 5-alpha reduced compound that can allow for gyno-type symptoms- this is due to a hydroxymethylene attachment on C2- no other DHT-derived compound has this structure- A-50 can act on the E receptor b/c of it
~Rosie
Team APPNUT